Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells
- Autores: Thomas Vahlenkamp, Raymond F. Schinazi, Katrin Hartmann
- Localización: American Journal of Veterinary Research, ISSN-e 1943-5681, ISSN 0002-9645, Nº. 2-75, 2014, págs. 273-281
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Objective�To compare cytotoxic effects and antiviral efficacy of 9 nucleoside reverse transcriptase inhibitors (NRTIs) against FIV in feline peripheral blood mononuclear cells.
Sample�Peripheral blood mononuclear cells obtained from 3 specific pathogen�free cats.
Procedures�3 of the 9 NRTIs had not been previously assessed in feline cell lines. Cytotoxic effects were determined by colorimetric quantification of a formazan product resulting from bioreduction of a tetrazolium reagent by viable peripheral blood mononuclear cells; uninfected cells from 1 cat were used in these assays. Cells from all 3 cats were infected with a pathogenic clone of FIV, and in vitro antiviral efficacy of each NRTI was assessed with an FIV p24 antigen capture ELISA.
Results�Cytotoxic effects in feline peripheral blood mononuclear cells were observed only at concentrations > 10 µM for all 9 NRTIs. Comparison of the cytotoxic effect at the highest concentration investigated (500µM) revealed that didanosine and amdoxovir were significantly less toxic than abacavir. All drugs induced a dose-dependent reduction of FIV replication. At the highest concentration investigated (10µM), there was no significant difference in antiviral efficacy among the test compounds.
Conclusions and Clinical Relevance�The evaluated NRTIs had low cytotoxicity against feline peripheral blood mononuclear cells and appeared to be safe options for further in vivo evaluation for the treatment of FIV-infected cats. There was no evidence suggesting that the newly evaluated compounds would be superior to the existing NRTIs for reducing FIV burden of infected cats.
